Septerna opened lower at $45.00, compared with its previous close of $45.23. In the last trading session, the stock traded between $43.82 and $45.43. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 3 years ago in Septerna is now worth
$ 207.24
giving a profit of
$ 107.24 (107.24%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.88 (-1.95%)
Day High
$45.43
Day Low
$43.82
Day Open
$45.00
Prev Close
$45.23
Volume
69,208
1W Return
8.55%
1M Return
13.20%
3M Return
31.85%
6M Return
89.13%
1Y Return
102.14%
Fundamentals
Market Cap ($ Mn)
2,070
PE Ratio
-
PB Ratio
4.59
PEG Ratio
-
ROE
-12.42%
ROCE
-14.82%
EPS (TTM)
-
Investment Returns
1 Week
8.55%
1 Month
13.20%
3 Months
31.85%
6 Months
89.13%
9 Months
86.34%
Financials
Quarterly
All values in $ Mn
0.2
Mar 25
0.1
Jun 25
21.5
Sep 25
24.1
Dec 25
26.5
Mar 26
26.7
Jun 26
Updates
25Aug
Septerna appoints Rajiv Patni as chief medical officer
Septerna appoints Rajiv Patni as chief medical officer to lead clinical development. Dr Patni joins from Judo Bio where he served as chief executive officer. He brings over 25 years of experience in biopharmaceutical R&D and regulatory affairs. Septerna focuses on developing oral medicines targeting G protein-coupled receptors.
2mo ago
11Aug
Septerna Q2 2026 Results: Revenue Surges to $26.7M on Novo Nordisk Collaboration
Septerna reported Q2 2026 revenue of $26.7 million, up sharply from $0.1 million in Q2 2025, fuelled by its Novo Nordisk collaboration including $14.6M upfront amortisation, $0.9M in milestones, and $11.2M in research services. Net loss narrowed to $13.0 million from $24.8 million, with cash of $516.5 million expected to fund operations at least into 2029. The Phase 1 study of SEP-479 for hypoparathyroidism showed a half-life of approximately three to four days supporting once-daily dosing, with SAD/MAD data expected in Q1 2027.
2mo ago
2Jul
Guggenheim lowers Septerna target to $45, maintains Buy
Guggenheim analyst Seamus Fernandez maintained a Buy rating on Septerna but lowered the price target to $45 from $52. This follows Truist Securities raising its target to $43 and HC Wainwright & Co. maintaining a target of $40.
4mo ago
9Jun
Raymond James raises Septerna price target to $53
Raymond James analyst Martin Auster maintained a Strong Buy rating on Septerna (NASDAQ: SEPN) and raised the price target to $53 from $47, signaling confidence in the stock's performance.
